Bridging the data gaps that impact retail and specialty-lite success

Learn how to leverage predictive analytics and measure top KPIs to maximize patient outcomes, provider engagement and brand performance on this webinar from PHIL and Syneos Health.

May 19, 2025

BioMarin to buy rare disease drugmaker Inozyme for $270M

The deal “fits like a glove” for BioMarin’s business, according to an analyst who also thinks there could be a “valuable” market opportunity for Inozyme’s main drug.

By Jacob Bell • May 16, 2025

Novo to work with Septerna in hunt for oral obesity drugs

The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the latest deal Novo has struck to expand its obesity pipeline.

By Gwendolyn Wu • May 14, 2025

GSK to buy liver disease drug for $1.2B

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver disease franchise.

By Kristin Jensen • May 14, 2025

Facing ‘uncertainty on steroids,’ biotech dealmakers tread more cautiously

Experts say market turmoil has made it harder for buyers and sellers to agree on price, which can be an especially imposing obstacle to large acquisitions.

By Jacob Bell • May 6, 2025

Merck KGaA to buy biotech SpringWorks for $3.9B

The deal, which has been in the works for months, hands the German pharmaceutical company two approved drugs for rare tumors.

By Ned Pagliarulo • April 28, 2025

Sanofi licenses immune disease drugs from startup Earendil

The startup, affiliated with China-based antibody designer Helixon Therapeutics, is developing bispecific drugs aimed at multiple popular immune disease targets, such as TL1A and IL23. 

By Kristin Jensen • April 17, 2025

Tempest seeks strategic alternatives as cash runs out for Phase 3 trial

Amid a funding drought for startups, the company is looking for a deal that can advance its liver cancer drug.

By Jonathan Gardner • April 10, 2025

GSK targets neurodegenerative diseases with latest licensing deal

The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across the blood-brain barrier.

By Jacob Bell • April 7, 2025

M&A recap: Big pharma starts the year mostly avoiding billion-dollar deals

Just two acquisitions in the first quarter, that of Intra-Cellular Therapies and IDRx, crossed the $1 billion mark, a notable decrease from the six seen during the same period last year.

By Jacob Bell • April 4, 2025

Bluebird gets rival takeout offer from Ayrmid

The new bid surpasses an offer SK Capital and Carlyle Group made last month for the gene therapy developer, which Bluebird’s board still supports.

By Ben Fidler • March 28, 2025

Merck bets $200M on a new type of heart pill

A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a genetic risk factor called lipoprotein(a). 

By Jonathan Gardner • March 25, 2025

Sanofi wagers $600M on a dual-targeting antibody drug for autoimmune disease

The deal with startup Dren Bio hands Sanofi a so-called myeloid cell engager that would compete with an array of programs aiming to “reset” the immune systems of people with inflammatory conditions. 

By Kristin Jensen • March 20, 2025

Taiho buys Swiss biotech and its ADC tech for $400M

The pharma will acquire Araris Biotech to gain access to three preclinical ADCs and a linking technology Araris claims is superior to existing platforms.

By Delilah Alvarado • March 17, 2025

AstraZeneca adds ‘in vivo’ cell therapy capabilities with EsoBiotech deal

The pharma is paying up to $1 billion to buy the Belgian startup, whose technology it sees as useful in treating cancer and autoimmune conditions.

By Ben Fidler • March 17, 2025

MeiraGTx spins Parkinson’s, obesity gene therapies into AI startup

The joint venture with generative AI firm Hologen hands MeiraGTx $200 million up front as well as other financial perks — a “transformative” deal, according to the company’s CEO.

By Jacob Bell • March 13, 2025

Mallinckrodt, Endo to combine in $7B deal

The merger will give the combined entity the financial flexibility to pursue drug licensing deals and broaden its therapeutic focus, executives said on a conference call.

By Kristin Jensen • March 13, 2025

Roche broadens obesity drug plans with $1.65B Zealand deal

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs it acquired from Carmot.

By Jonathan Gardner • March 12, 2025

Viking inks CordenPharma deal to boost obesity drug supply

The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched weight loss treatment.

By Jonathan Gardner • March 11, 2025

2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M

The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly all of its market value.

By Ben Fidler • March 11, 2025

Jazz expands in oncology with $935M deal for Chimerix

Chimerix is currently awaiting an FDA decision on accelerated approval of a drug it’s developing for a type of glioma. 

By Jonathan Gardner • March 5, 2025

AbbVie gets into obesity with $350M deal for once-weekly shot

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with drugs from Novo Nordisk, Eli Lilly and Zealand.

By Jonathan Gardner • March 3, 2025

AstraZeneca deepens China presence with FibroGen deal

The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through government investigations into its business practices there. 

By Kristin Jensen • Feb. 20, 2025

FTC retains stricter merger guidelines under Trump

Agency chair Andrew Ferguson sent a memo to staff on Tuesday clarifying that Biden-era guidelines will remain in place — for now.

By Rebecca Pifer • Feb. 19, 2025

Biogen buys rights to Stoke’s rare epilepsy drug

In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet syndrome.

By Jacob Bell • Feb. 18, 2025